AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01256-06v1
51/3/1109    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, A. T.
Right arrow Articles by Sullivan, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, A. T.
Right arrow Articles by Sullivan, W. J., Jr.
Antimicrobial Agents and Chemotherapy, March 2007, p. 1109-1111, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01256-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii{triangledown}

Aaron T. Smith,1 Meredith R. Livingston,1 Antonello Mai,2 Patrizia Filetici,3 Sherry F. Queener,1 and William J. Sullivan Jr.1*

Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, Indiana,1 Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Studi Farmaceutici, Universita degli Studi di Roma "La Sapienza," P.le A. Moro 5, I-00185 Rome, Italy,2 Istituto di Biologia e Patologia Molecolari CNR, Dipartimento Genetica e Biologia Molecolare, Universita degli Studi di Roma "La Sapienza," P.le A. Moro 5, I-00185 Rome, Italy3

Received 6 October 2006/ Returned for modification 19 November 2006/ Accepted 6 December 2006

We report that quinoline derivative MC1626, first described as an inhibitor of the histone acetyltransferase (HAT) GCN5, is active against the protozoan parasite Toxoplasma gondii in vitro. However, MC1626 does not inhibit Toxoplasma GCN5 HATs or reduce HAT-mediated activity; rather, this quinoline may target the plastid organelle called the apicoplast.

* Corresponding author. Mailing address: Department of Pharmacology & Toxicology, IU Center For AIDS Research, Indiana University School of Medicine, 635 Barnhill Drive, MS A-525, Indianapolis, IN 46202. Phone: (317) 274-1573. Fax: (317) 274-7714. E-mail: wjsulliv{at}iupui.edu.

{triangledown} Published ahead of print on 18 December 2006.

Antimicrobial Agents and Chemotherapy, March 2007, p. 1109-1111, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01256-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.